Virtual Reality and Relaxation for the Treatment of Generalized Anxiety Disorders: a Comparative Study With Standard Relaxation (Relax-TAG)

The purpose is threefold: Assess the anxiety reduction, the mood positive effect and the rise of quality of life when using methods of relaxation combined with virtual reality with patients suffering from generalized anxiety disorder in comparison of the effect of traditional relaxation therapy. Observe and evaluate the effect of perceived presence in synthetic environments in the virtual experience of relaxation. Evaluate the therapeutic efficacy of stereoscopy during exposure to relaxing virtual environments for the treatment of generalized anxiety disorder.

It is a comparative, randomized, two groups study (29 in each group):

  • Relaxation optimized virtual reality
  • Classical relaxation (without Virtual Reality). The protocol comprised for each groups 7 relaxing sessions (with or without virtual reality epending on the group). Each session lasted for approximately 30 to 35 minutes, including a 5-minute pause between immersive trials, in order to avoid cyber sickness in the virtual reality group.

Expected results: a measurable therapeutic improvement produced by the combination of relaxation and virtual and its additional effect when compared to the traditional treatment.

Measurements of variables and therapeutic effects will be carried out with psychometric measures.

The creation process of the relaxing virtual environments has already been completed. The virtual environments are ready for use.

The apparatus needed and in our possession include:

  • A laptop for generating virtual environments
  • A stereoscopic display
  • Apparatus for physiological measurements

Study Overview

Study Type

Interventional

Enrollment (Actual)

58

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Marseille, France, 13354
        • Assistance Publique Hopitaux de Marseille

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Male or Female.
  • Age 18-65 years inclusive.
  • Generalized Anxiety Disorders primary diagnosis in patients according with major depressive episode V (DSM-V) criteria.
  • Topic speaking English or French language
  • Subject who have signed a written informed consent and undertaking to comply with the instructions of the protocol.

Exclusion Criteria:

  • Subject not having at least one inclusion criterion;
  • Minor Subject, pregnant or nursing women, about not being affiliated to the social security scheme, or deprived of liberty subject;
  • Age greater than 18 and less than 65 years.
  • Subject Trust;
  • Subject indication against having a virtual reality: epilepsy, major organ failure, severe myopia, acute psychiatric disorder (such as schizophrenia in acute period, paranoia, manic, or melancholic major depression).
  • Subject did not sign the informed consent, or topic for which the legal representative has not signed this consent in cases where the subject is under curatorship.
  • Subject wishing to interrupt his participation in the study before the end;
  • Subject for which the occurrence of an event makes it necessary to interrupt the therapy program before the end
  • History of neurological disease, head injury or mental retardation.
  • Presence of a psychotic disorder decompensated
  • Presence of addictologique comorbidity.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Relaxation optimized virtual reality
six relaxation sessions with virtual reality
Experimental: Classical relaxation (without Virtual Reality).
six relaxation sessions without virtual reality

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
scores on psychometric scales in connection with the Generalized Anxiety Disorders (TAG)
Time Frame: 24 months
Penn State Worry Questionnaire
24 months

Secondary Outcome Measures

Outcome Measure
Time Frame
Short self-completion questionnaire on the Generalized Anxiety Disorders (TAG)
Time Frame: 24 months
24 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 13, 2015

Primary Completion (Actual)

October 3, 2017

Study Completion (Actual)

May 25, 2023

Study Registration Dates

First Submitted

October 7, 2015

First Submitted That Met QC Criteria

October 7, 2015

First Posted (Estimated)

October 8, 2015

Study Record Updates

Last Update Posted (Actual)

May 26, 2023

Last Update Submitted That Met QC Criteria

May 25, 2023

Last Verified

May 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • 2015-23

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Generalized Anxiety Disorders

Clinical Trials on Relaxation optimized virtual reality

3
Subscribe